Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QR9 | ISIN: FR0012616852 | Ticker-Symbol: 609
Frankfurt
06.06.25 | 08:04
1,220 Euro
+0,16 % +0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ABIONYX PHARMA SA Chart 1 Jahr
5-Tage-Chart
ABIONYX PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,2741,27817:25

Aktuelle News zur ABIONYX PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital208Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX) Market:...
► Artikel lesen
28.05.ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2025262Consolidated sales of 1 M€ at end March 2025 Cash position of 4.1 M€ at March 31, 2025 before collection of Research Tax Credit of 1.08 M€ Anticipated key milestone: feedback from...
► Artikel lesen
06.05.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital227Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
03.04.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital328Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
21.03.CIC Market Solutions Initiates Buy Coverage of ABIONYX Pharma289Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), next-generation biopharma dedicated to the development of innovative biomedicines based on recombinant apolipoprotein apoA-I...
► Artikel lesen
17.03.ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2024210Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein...
► Artikel lesen
ABIONYX PHARMA Aktie jetzt für 0€ handeln
05.03.ABIONYX Pharma Announces Its 2024 Full-Year Results291Improved profitability of IRIS Pharma with a net income of 6% of revenues Extended financial visibility to the 2nd quarter of 2026 after the support of the France 2030 plan Regulatory...
► Artikel lesen
04.03.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital240Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
28.02.ABIONYX Pharma: World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances268Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis Preparation for the submission of the Marketing Authorization Application...
► Artikel lesen
28.02.ABIONYX Pharma: World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances297Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis Preparation for the submission of the Marketing Authorization Application...
► Artikel lesen
27.02.ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2024545Consolidated revenue of €4.6m in 2024 Available cash of €3.2m at December 31, 2024 Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX eligible for PEA PME), a next generation biopharma...
► Artikel lesen
20.02.ABIONYX Pharma, winner of the France 2030 Plan's "i-Démo" call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide390ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant...
► Artikel lesen
10.02.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital208Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
13.01.ABIONYX Pharma Announces Its Financial Calendar for the Year 2025337Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's...
► Artikel lesen
08.01.ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital274Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
05.12.24ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital257Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
29.11.24ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024510Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's...
► Artikel lesen
14.11.24ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024472Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma's CIR (€610k) as of September 30, 2024 Live broadcast of the General...
► Artikel lesen
07.11.24ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on November 28, 2024, and the Availability of Related Documents763Proposed appointment of Jean-Gérard Galvez, Luc Demarre and Caroline DeSurmont as directors Proposed financial delegations necessary for the Company's development Proposed amendments...
► Artikel lesen
05.11.24ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital308Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1